Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study. - Mall MA; Wainwright CE; Legg J; Chilvers M; Gartner S; Dittrich AM; Stehling F; Conner S; Grant S; Suresh N; Weinstock TG; Davies JC (The European respiratory journal, 2025)